Patent 11419823

Litigation summary

Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.

Active provider: Google · gemini-2.5-flash

No PTAB proceedings on file. This patent has not been challenged through Inter Partes Review, Post-Grant Review, or Covered Business Method review at the USPTO. The absence is itself a signal — well-asserted patents eventually attract IPRs.

Cases on file (5)

Group view →

Specific litigation cases in our database that name US patent 11419823. The free-form analysis below may also discuss cases beyond this list.

Litigation summary

Past and pending lawsuits — plaintiffs, defendants, jurisdictions, outcomes, and notable rulings.

✓ Generated

As a patent attorney, I have reviewed the litigation landscape for US patent 11,419,823.

Here's a list of known litigation involving US Patent 11,419,823:

  1. Case Name: Veloxis Pharmaceuticals, Inc. v. Accord Healthcare, Inc. and [Intas Pharmaceuticals LTD.](/litigations/by-defendant/Intas%20Pharmaceuticals%20LTD.)

    • Plaintiff(s): Veloxis Pharmaceuticals, Inc.
    • Defendant(s): Accord Healthcare, Inc. and Intas Pharmaceuticals LTD.
    • Jurisdiction: U.S. District Court for the District of Delaware
    • Filing Date: July 7, 2022. (The Google Patents entry mentions a case filed on 2022-07-07 in D. Delaware for this patent, and Law Street Media details a complaint filed by Veloxis against Accord and Intas on July 7, 2022, in the District of Delaware, citing US11419823 as one of the patents-in-suit.)
    • Outcome/Current Status: The case alleges patent infringement due to the defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA, seeking to market generic tacrolimus extended-release tablets before the expiration of Veloxis's patents, including US11419823. Veloxis is seeking favorable judgment, an order preventing the defendants from manufacturing their ANDA products, damages, and litigation fees.

  2. Case Name: Veloxis Pharmaceuticals, Inc. v. Sun Pharmaceutical Industries Ltd.

    • Plaintiff(s): Veloxis Pharmaceuticals, Inc.
    • Defendant(s): Sun Pharmaceutical Industries Ltd.
    • Jurisdiction: District Court, D. Delaware
    • Filing Date: June 19, 2024.
    • Outcome/Current Status: The current status indicates "Start Trial".

  3. Case Name: Veloxis Pharma Inc v. Alkem Laboratories Ltd.

    • Plaintiff(s): Veloxis Pharma Inc.
    • Defendant(s): Alkem Laboratories Ltd.
    • Jurisdiction: U.S. District Court for the District of Delaware
    • Case Number: 1:24-cv-00784
    • Filing Date: July 3, 2024.
    • Outcome/Current Status: The case is "Closed". It is categorized under "ANDA" (Abbreviated New Drug Application) nature of suit.

  4. Case Name: Veloxis Pharmaceuticals, Inc. v. Glenmark Pharmaceuticals Inc., USA

    • Plaintiff(s): Veloxis Pharmaceuticals, Inc.
    • Defendant(s): Glenmark Pharmaceuticals Inc., USA
    • Jurisdiction: U.S. District Court for the District of Delaware
    • Case Number: 1:2025cv00458
    • Filing Date: A "Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA)" was filed on April 14, 2025, noting that the patentee received notice no earlier than March 4, 2025.
    • Outcome/Current Status: The case is ongoing, with filings such as proposed protective orders and scheduling orders occurring in August 2025.

The previous patent summary also indicated litigation filed in Delaware District Court with case numbers 1:25-cv-00458, 1:24-cv-00784, and 1:24-cv-00726. Case 1:25-cv-00458 aligns with Veloxis v. Glenmark. Case 1:24-cv-00784 aligns with Veloxis v. Alkem Laboratories. The details for case 1:24-cv-00726 were not readily available in the search results for specific identification of plaintiff, defendant, and status beyond its existence in the Delaware District Court as general litigation related to the patent.

Generated 5/30/2026, 6:48:14 AM